Interferon regulatory factor 1 binding to p300 stimulates DNA-dependent acetylation of p53

被引:64
作者
Dornan, D
Eckert, M
Wallace, M
Shimizu, H
Ramsay, E
Hupp, TR
Ball, KL
机构
[1] Univ Edinburgh, Western Gen Hosp, Ctr Canc Res, Cell Signalling Unit,CRUK Interferon & Cell Signa, Edinburgh EH4 2XR, Midlothian, Scotland
[2] Univ Edinburgh, Western Gen Hosp, Ctr Canc Res, Cell Signalling Unit,CRUK P53 Signal Transduct Gr, Edinburgh EH4 2XR, Midlothian, Scotland
关键词
D O I
10.1128/MCB.24.22.10083-10098.2004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Interferon regulatory factor 1 (IRF-1) and p53 control distinct sets of downstream genes; however, these two antioncogenic transcription factors converge to regulate p21 gene expression and to inhibit tumor formation. Here we investigate the mechanism by which IRF-1 and p53 synergize at the p21 promoter and show that stimulation of p21 transcription by IRF-1 does not require its DNA-binding activity but relies on the ability of IRF-1 to bind the coactivator p300 and to stimulate p53-dependent transcription by an allosteric mechanism. Deletion of the p300-binding sites in IRF-1 eliminates the ability of IRF-1 to stimulate p53 acetylation and associated p53 activity. Complementing this, small peptides derived from the IRF-1-p300 interface can bind to p300, stabilize the binding of p300 to DNA-bound p53, stimulate p53 acetylation in trans, and up-regulate p53-dependent activity from the p21 promoter. The nonacetylatable p53 mutant (p53-6KR) cannot be stimulated by IRF-1, further suggesting that p53 acetylation is the mechanism whereby IRF-1 modifies p53 activity. These data expand the core p300-p53 protein LXXLL and PXXP interface by including an IRF-1-p300 interface as an allosteric modifier of DNA-dependent acetylation of p53 at the p21 promoter.
引用
收藏
页码:10083 / 10098
页数:16
相关论文
共 40 条
[21]   Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53 [J].
Nozawa, H ;
Oda, E ;
Nakao, K ;
Ishihara, M ;
Ueda, S ;
Yokochi, T ;
Ogasawara, K ;
Nakatsuru, Y ;
Shimizu, S ;
Ohira, Y ;
Hioki, K ;
Aizawa, S ;
Ishikawa, T ;
Katsuki, M ;
Muto, T ;
Taniguchi, T ;
Tanaka, N .
GENES & DEVELOPMENT, 1999, 13 (10) :1240-1245
[22]   Common deleted region on the long arm of chromosome 5 in esophageal carcinoma [J].
Ogasawara, S ;
Tamura, G ;
Maesawa, C ;
Suzuki, Y ;
Ishida, K ;
Satoh, N ;
Uesugi, N ;
Saito, K ;
Satodate, R .
GASTROENTEROLOGY, 1996, 110 (01) :52-57
[23]   Decision making by p53: life, death and cancer [J].
Oren, M .
CELL DEATH AND DIFFERENTIATION, 2003, 10 (04) :431-442
[24]   Analysis of chromatin structure by in vivo formaldehyde cross-linking [J].
Orlando, V ;
Strutt, H ;
Paro, R .
METHODS-A COMPANION TO METHODS IN ENZYMOLOGY, 1997, 11 (02) :205-214
[25]   Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway [J].
Pamment, J ;
Ramsay, E ;
Kelleher, M ;
Dornan, D ;
Ball, KL .
ONCOGENE, 2002, 21 (51) :7776-7785
[26]   Altered DNA repair and dysregulation of p53 in IRF-1 null hepatocytes [J].
Prost, S ;
Bellamy, COC ;
Cunningham, DS ;
Harrison, DJ .
FASEB JOURNAL, 1998, 12 (02) :181-188
[27]   DNA damage activates p53 through a phosphorylation-acetylation cascade [J].
Sakaguchi, K ;
Herrera, JE ;
Saito, S ;
Miki, T ;
Bustin, M ;
Vassilev, A ;
Anderson, CW ;
Appella, E .
GENES & DEVELOPMENT, 1998, 12 (18) :2831-2841
[28]   Molecular mechanism of the interaction between MDM2 and p53 [J].
Schon, O ;
Friedler, A ;
Bycroft, M ;
Freund, SMV ;
Fersht, AR .
JOURNAL OF MOLECULAR BIOLOGY, 2002, 323 (03) :491-501
[29]   Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus binds to p53 and represses p53-dependent transcription and apoptosis [J].
Seo, T ;
Park, J ;
Lee, D ;
Hwang, SG ;
Choe, J .
JOURNAL OF VIROLOGY, 2001, 75 (13) :6193-6198
[30]  
Shieh SY, 2000, GENE DEV, V14, P289